יחס חוב לטווח קצר להון עצמי: Alterity Therapeutics Limited (ATHE)

Alterity Therapeutics (ATHE) focuses on developing therapies for neurodegenerative pathologies by utilizing molecules to control metal exchange in the brain. This chart of stock quotes demonstrates the debt-to-equity dynamics, which stands at 0.00. High barriers to entry are driven by patents and strict FDA oversight. Meanwhile, the company adheres to environmental standards regarding biohazardous waste disposal in its laboratories.

This ratio measures the proportion of liabilities maturing within one year relative to equity, allowing for an assessment of liquidity risk and interest rate sensitivity. For Alterity Therapeutics (ATHE), which invests in combating neurodegeneration in Parkinson's disease, the trend of short-term liabilities to equity serves as an indicator of financial stability when funding costly cellular research.